Market revenue in 2022 | USD 11,301.3 million |
Market revenue in 2030 | USD 21,483.3 million |
Growth rate | 8.4% (CAGR from 2022 to 2030) |
Largest segment | Hormonal therapy |
Fastest growing segment | Hormonal Therapy |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy, Other Drug Class, Hormonal Therapy |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to prostate cancer therapeutics market will help companies and investors design strategic landscapes.
hormonal therapy was the largest segment with a revenue share of 88.42% in 2022. Horizon Databook has segmented the Global prostate cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy, other drug class, hormonal therapy covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global prostate cancer therapeutics market , including forecasts for subscribers. This global databook contains high-level insights into Global prostate cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account